CLAIMS

1. Use of a pharmaceutical composition comprising fimasartan, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof in the manufacture of a medicament for preventing or treating diabetic nephropathy.

2. The use according to claim 1, wherein the pharmaceutically acceptable salt is a fimasartan potassium salt.

3. The use according to claim 1, wherein the hydrate is a fimasartan potassium salt trihydrate.

4. The use according to claim 1, wherein the composition further contains pharmaceutically acceptable additives.

5. The use according to claim 1, wherein the composition is for oral administration.

6. The use according to claim 1, wherein the composition contains, based on the total weight of the composition, 5 wt% to 60 wt% of fimasartan, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.